Happy New Year 2021. I am challenging myself with a weekly science blog on my website. The articles will be compiled and posted here with #ThisWeekInScience or #TWiS. Looking forward to another soul-satisfying journey this year. 🙏 https://t.co/mtx30RMNng— Tryambak Srivastava (@imtryam) January 1, 2021
Science based blogs which shall be updated in here.
Watch this space.
Jasleen, a young mother of two, had a lump in her breast when she first noticed something wasn’t quite right. Her body suffered as a result of the several therapies she underwent throughout her treatment. Despite the difficulties, Jasleen was committed to fighting the illness, and she had a team of medical experts by her side who gave her the best care. Jasleen finally entered remission following several months of treatment, emerging stronger and more resilient than before. She is an inspiration to anyone experiencing comparable difficulties because of the lessons learned through her journey about the value of early detection, resiliency, and hope.
Gomes et al. report that MMA levels are significantly higher in the blood of healthy people over the age of 60 than in those under 30. The elevated level of MMA had not caused ill health in the individuals studied. However, the authors found that treating human cancer cells with serum from the blood of the older group, or with high concentrations of MMA, led them to adopt characteristics of metastatic cancer cells — those that can spread from a primary tumour to seed cancers elsewhere in the body. These characteristics include a loss of cell–cell attachment and an increase in mobility. When injected into mice, the cells formed metastatic tumours in the lungs.
In this #TWiS post, I describe in details the recent efficacy story of the Bharat Biotech and Indian Council of Medical Research – National Institute of Virology COVAXIN based on their recent The Lancet Infectious Diseases paper. This blog summarises the findings of phase 1, 2 trials and the interim analysis of phase 3 trial. Proud to have received the two doses of CAVIXN at AIIMS, New Delhi.